ES2698359T3 - Agonistas del receptor de la esfingosina-1-fosfato, métodos para preparar los mismos y composiciones farmacéuticas que los contienen como agentes activos - Google Patents
Agonistas del receptor de la esfingosina-1-fosfato, métodos para preparar los mismos y composiciones farmacéuticas que los contienen como agentes activos Download PDFInfo
- Publication number
- ES2698359T3 ES2698359T3 ES14753476T ES14753476T ES2698359T3 ES 2698359 T3 ES2698359 T3 ES 2698359T3 ES 14753476 T ES14753476 T ES 14753476T ES 14753476 T ES14753476 T ES 14753476T ES 2698359 T3 ES2698359 T3 ES 2698359T3
- Authority
- ES
- Spain
- Prior art keywords
- isopropyl
- oxadiazol
- dihydro
- methyl
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HGPVTSXCIFGEST-UHFFFAOYSA-N CC(C(CO)N)=O Chemical compound CC(C(CO)N)=O HGPVTSXCIFGEST-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)*1c(ccc(COc2ccc3C(N)=C(C*(CC4)CCC4C(OC)=O)CCc3c2)c2)c2C(C)=*1 Chemical compound CC(C)*1c(ccc(COc2ccc3C(N)=C(C*(CC4)CCC4C(OC)=O)CCc3c2)c2)c2C(C)=*1 0.000 description 1
- YFNOIGITOJRQRJ-UHFFFAOYSA-N CC(C)C[n](cc1)c(cc2)c1cc2-c1nc(-c2c(C)cc(CN(C3)CC3C(O)=O)cc2)n[o]1 Chemical compound CC(C)C[n](cc1)c(cc2)c1cc2-c1nc(-c2c(C)cc(CN(C3)CC3C(O)=O)cc2)n[o]1 YFNOIGITOJRQRJ-UHFFFAOYSA-N 0.000 description 1
- WIDXEYILRKFVGH-UHFFFAOYSA-N CC(C)NCCS(C)(=O)=O Chemical compound CC(C)NCCS(C)(=O)=O WIDXEYILRKFVGH-UHFFFAOYSA-N 0.000 description 1
- DVMUIWSXKZCERQ-UHFFFAOYSA-N CC(C)Nc1ncc(COc(cc2)cc3c2C(Cl)=C(CN(CC2)CCC2C(O)=O)CC3)cc1C(Cl)=N Chemical compound CC(C)Nc1ncc(COc(cc2)cc3c2C(Cl)=C(CN(CC2)CCC2C(O)=O)CC3)cc1C(Cl)=N DVMUIWSXKZCERQ-UHFFFAOYSA-N 0.000 description 1
- UGLZGDMALCQWIE-UHFFFAOYSA-N CC(C)[n](c1ccc(COc2ccc3C(Cl)=C(CN(CC4)CC4(C(O)=O)F)CCc3c2)cc11)nc1Cl Chemical compound CC(C)[n](c1ccc(COc2ccc3C(Cl)=C(CN(CC4)CC4(C(O)=O)F)CCc3c2)cc11)nc1Cl UGLZGDMALCQWIE-UHFFFAOYSA-N 0.000 description 1
- PZXZGVMNVFUQRH-UHFFFAOYSA-N CC(C)[n](cc(c1c2)C#N)c1ccc2-c1nc(-c2c(CCN(CC(O)=O)C3)c3ccc2)n[o]1 Chemical compound CC(C)[n](cc(c1c2)C#N)c1ccc2-c1nc(-c2c(CCN(CC(O)=O)C3)c3ccc2)n[o]1 PZXZGVMNVFUQRH-UHFFFAOYSA-N 0.000 description 1
- FUURQSYPXBIVQD-UHFFFAOYSA-N CC(C)[n](cc(c1c2)Cl)c1ccc2-c1nc(-c2c(C)c(CN(C)CCC(O)=O)ccc2)n[o]1 Chemical compound CC(C)[n](cc(c1c2)Cl)c1ccc2-c1nc(-c2c(C)c(CN(C)CCC(O)=O)ccc2)n[o]1 FUURQSYPXBIVQD-UHFFFAOYSA-N 0.000 description 1
- UNTZBNRBMGBEFX-UHFFFAOYSA-N CC(C)[n](cc1)c(cc2)c1cc2-c1nc(-c2cccc3c2CCCC3N)n[o]1 Chemical compound CC(C)[n](cc1)c(cc2)c1cc2-c1nc(-c2cccc3c2CCCC3N)n[o]1 UNTZBNRBMGBEFX-UHFFFAOYSA-N 0.000 description 1
- OCRXCKSQMKHOJQ-UHFFFAOYSA-N CC(C)[n](ccc1c2)c1ccc2-c1nc(-c2c(C)cc(CN(C)CCC(O)=O)cc2)n[o]1 Chemical compound CC(C)[n](ccc1c2)c1ccc2-c1nc(-c2c(C)cc(CN(C)CCC(O)=O)cc2)n[o]1 OCRXCKSQMKHOJQ-UHFFFAOYSA-N 0.000 description 1
- YVNQQMIWULKBKQ-UHFFFAOYSA-N CC(C)[n](ccc1c2)c1ccc2-c1nc(-c2cc(CN(CC(NCCO)=O)CC3)c3cc2)n[o]1 Chemical compound CC(C)[n](ccc1c2)c1ccc2-c1nc(-c2cc(CN(CC(NCCO)=O)CC3)c3cc2)n[o]1 YVNQQMIWULKBKQ-UHFFFAOYSA-N 0.000 description 1
- FOSQBMBQLNVRPX-UHFFFAOYSA-N CC(C)[n]1c(ccc(-c2nc(-c3c(C)cc(CCC(O)=O)cc3)n[o]2)c2)c2c(Cl)c1 Chemical compound CC(C)[n]1c(ccc(-c2nc(-c3c(C)cc(CCC(O)=O)cc3)n[o]2)c2)c2c(Cl)c1 FOSQBMBQLNVRPX-UHFFFAOYSA-N 0.000 description 1
- VTHOUBSEYRRQAZ-UHFFFAOYSA-N CC(C)[n]1ncc2c1ccc(-c1nc(-c3c(C)cc(CNCC(O)=O)cc3)n[o]1)c2 Chemical compound CC(C)[n]1ncc2c1ccc(-c1nc(-c3c(C)cc(CNCC(O)=O)cc3)n[o]1)c2 VTHOUBSEYRRQAZ-UHFFFAOYSA-N 0.000 description 1
- TVCUWYDUNSBMMF-UHFFFAOYSA-N CC(C)[n]1ncc2c1ccc(COc1cccc3c1CCN(CCC(O)=O)C3)c2 Chemical compound CC(C)[n]1ncc2c1ccc(COc1cccc3c1CCN(CCC(O)=O)C3)c2 TVCUWYDUNSBMMF-UHFFFAOYSA-N 0.000 description 1
- BIKQZMQACYLOEE-UHFFFAOYSA-N CC(CC(NCCO)O)I Chemical compound CC(CC(NCCO)O)I BIKQZMQACYLOEE-UHFFFAOYSA-N 0.000 description 1
- XGHCCKYOVMLCAC-UHFFFAOYSA-N CN(CCC1=CC=[I]C(c2n[o]c(-c(cc3)cc(c(Cl)c4)c3[n]4[I](C)C)n2)=C1)CC(O)=O Chemical compound CN(CCC1=CC=[I]C(c2n[o]c(-c(cc3)cc(c(Cl)c4)c3[n]4[I](C)C)n2)=C1)CC(O)=O XGHCCKYOVMLCAC-UHFFFAOYSA-N 0.000 description 1
- RFHQPDXWPUYAJN-UHFFFAOYSA-N CNC(N(C1)CC1O)=O Chemical compound CNC(N(C1)CC1O)=O RFHQPDXWPUYAJN-UHFFFAOYSA-N 0.000 description 1
- FOTAKIBRBUYAPM-UHFFFAOYSA-N CNC(N(CC1)CC1O)=O Chemical compound CNC(N(CC1)CC1O)=O FOTAKIBRBUYAPM-UHFFFAOYSA-N 0.000 description 1
- FVTRBVTTXUFELR-UHFFFAOYSA-N Cc(cc(CCC(O)=O)cc1)c1-c1n[o]c(-c(cc2)cc3c2[n](C)cc3)n1 Chemical compound Cc(cc(CCC(O)=O)cc1)c1-c1n[o]c(-c(cc2)cc3c2[n](C)cc3)n1 FVTRBVTTXUFELR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130018293 | 2013-02-20 | ||
| PCT/KR2014/001336 WO2014129796A1 (en) | 2013-02-20 | 2014-02-19 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2698359T3 true ES2698359T3 (es) | 2019-02-04 |
Family
ID=51391525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14753476T Active ES2698359T3 (es) | 2013-02-20 | 2014-02-19 | Agonistas del receptor de la esfingosina-1-fosfato, métodos para preparar los mismos y composiciones farmacéuticas que los contienen como agentes activos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9540362B2 (pl) |
| EP (1) | EP2958913B1 (pl) |
| JP (1) | JP6294359B2 (pl) |
| KR (1) | KR101939657B1 (pl) |
| CN (1) | CN105051037B (pl) |
| AU (1) | AU2014219575B2 (pl) |
| BR (1) | BR112015019794B1 (pl) |
| DK (1) | DK2958913T3 (pl) |
| ES (1) | ES2698359T3 (pl) |
| HU (1) | HUE039931T2 (pl) |
| MX (1) | MX370032B (pl) |
| PL (1) | PL2958913T3 (pl) |
| PT (1) | PT2958913T (pl) |
| RU (1) | RU2654483C2 (pl) |
| SI (1) | SI2958913T1 (pl) |
| TW (1) | TWI582073B (pl) |
| WO (1) | WO2014129796A1 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| KR102644587B1 (ko) * | 2015-12-24 | 2024-03-07 | (주)아모레퍼시픽 | 유사 세라마이드 화합물 및 그 제조방법 |
| WO2017131149A1 (ja) * | 2016-01-29 | 2017-08-03 | 小野薬品工業株式会社 | テトラヒドロナフタレン誘導体 |
| RU2754845C2 (ru) * | 2016-07-22 | 2021-09-08 | Медшайн Дискавери Инк. | Агонист s1p1 и его применение |
| JP7178357B2 (ja) | 2017-03-07 | 2022-11-25 | エフ．ホフマン－ラ ロシュ アーゲー | オキサジアゾール一過性受容器電位チャネル阻害剤 |
| CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
| KR101891051B1 (ko) * | 2018-01-29 | 2018-08-31 | 주식회사 세종바이오메드 | 스핑고신-1-포스페이트 유사체 및 이의 합성 방법 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| CA3126021A1 (en) | 2019-01-11 | 2020-07-16 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
| CN110240537B (zh) * | 2019-05-22 | 2022-06-21 | 成都阿奇生物医药科技有限公司 | 一种茚氧乙酸类化合物及其制备方法和用途 |
| MY199797A (en) * | 2019-12-03 | 2023-11-23 | Lg Chemical Ltd | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient |
| KR20210073998A (ko) | 2019-12-11 | 2021-06-21 | 주식회사 엘지화학 | 다발성 경화증 예방 또는 치료용 약제학적 조성물 |
| CN116437921A (zh) * | 2020-09-28 | 2023-07-14 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的用途 |
| WO2022065940A1 (ko) * | 2020-09-28 | 2022-03-31 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 용도 |
| WO2022080812A1 (ko) * | 2020-10-13 | 2022-04-21 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
| KR102647663B1 (ko) * | 2020-10-13 | 2024-03-14 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
| WO2022220608A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| CN117177964B (zh) * | 2021-04-14 | 2026-05-08 | 株式会社Lg化学 | 制备鞘氨醇-1-磷酸酯受体激动剂的新方法 |
| KR102885760B1 (ko) | 2021-04-14 | 2025-11-13 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법 |
| TWI894459B (zh) * | 2021-04-14 | 2025-08-21 | 南韓商Ｌｇ化學股份有限公司 | 製備用於合成鞘胺醇—１—磷酸酯受體促效劑之中間體的方法 |
| CN117202893A (zh) * | 2021-04-14 | 2023-12-08 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物 |
| KR102806317B1 (ko) * | 2021-04-14 | 2025-05-13 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| CN117136183B (zh) * | 2021-04-14 | 2026-03-31 | 株式会社Lg化学 | 制备鞘氨醇-1-磷酸酯受体激动剂的新方法 |
| KR20220142379A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 엘지화학 | 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법 |
| US20240228441A1 (en) * | 2021-04-14 | 2024-07-11 | Lg Chem, Ltd. | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist |
| EP4324826A4 (en) * | 2021-04-14 | 2024-08-21 | Lg Chem, Ltd. | CRYSTALLINE FORM OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST |
| KR102815426B1 (ko) * | 2021-04-14 | 2025-05-30 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 약제학적으로 허용되는 염 및 이의 결정형 |
| CN117120425A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的晶体形式 |
| WO2022220600A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| CN117120037A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 包含具有受控粒度的鞘氨醇-1-磷酸酯受体激动剂的药物组合物 |
| KR102533409B1 (ko) | 2021-11-04 | 2023-05-26 | 주식회사 넥스트젠바이오사이언스 | 2-아미노-2-(2-(1-데실-1h-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올의 신규염 및 이를 포함하는 약학적 조성물 |
| EP4567034A1 (en) * | 2022-08-01 | 2025-06-11 | Korea Institute of Science and Technology | Novel heterocyclyl-phenyl-methylamine derivative, preparation method therefor, and use thereof for prevention, alleviation, or treatment of multiple sclerosis |
| CN117126150B (zh) * | 2023-08-29 | 2026-05-15 | 仁合益康集团有限公司 | 一种阿齐沙坦酯钾盐杂质a的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8750298A (en) * | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| JP2006516254A (ja) | 2003-01-06 | 2006-06-29 | イーライ・リリー・アンド・カンパニー | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 |
| WO2004092116A1 (en) | 2003-04-10 | 2004-10-28 | Amgen, Inc. | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CA2591399C (en) | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| US7528132B2 (en) | 2005-01-26 | 2009-05-05 | Schering Corporation | Kinase inhibitors |
| EP1996191A4 (en) | 2006-03-02 | 2010-05-19 | Glaxosmithkline Llc | THIAZOLONE AS A PI3 KINASE INHIBITOR |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| JP2009269819A (ja) * | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| JP2010510250A (ja) | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ |
| US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| BRPI0815042A2 (pt) | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| US8153103B2 (en) | 2008-07-01 | 2012-04-10 | Board Of Regents, The University Of Texas System | Conjugates of photo-activatable dyes |
| CA2739901A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
| US8741923B2 (en) | 2008-12-18 | 2014-06-03 | Merck Serono Sa | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| US20100174539A1 (en) | 2009-01-06 | 2010-07-08 | Qualcomm Incorporated | Method and apparatus for vector quantization codebook search |
| WO2010093191A2 (en) | 2009-02-13 | 2010-08-19 | Lg Life Sciences Ltd. | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
| EP2241558A1 (en) | 2009-04-03 | 2010-10-20 | Merck Serono SA | Oxadiazole derivatives |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| TW201107302A (en) | 2009-06-26 | 2011-03-01 | Glaxo Group Ltd | Compounds |
| HUE036391T2 (hu) | 2009-11-13 | 2018-07-30 | Celgene Int Ii Sarl | Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások |
| CN105130922A (zh) | 2009-11-13 | 2015-12-09 | 瑞塞普托斯公司 | 选择性的杂环1-磷酸鞘氨醇受体调节剂 |
| JP5939158B2 (ja) * | 2009-11-24 | 2016-06-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 治療的有用性を有する受容体調節物質としての新規化合物 |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| EP2643297A1 (en) * | 2010-11-24 | 2013-10-02 | Allergan, Inc. | Indole derivatives as modulators of s1p receptors |
| TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
-
2014
- 2014-02-19 HU HUE14753476A patent/HUE039931T2/hu unknown
- 2014-02-19 PL PL14753476T patent/PL2958913T3/pl unknown
- 2014-02-19 AU AU2014219575A patent/AU2014219575B2/en active Active
- 2014-02-19 US US14/764,116 patent/US9540362B2/en active Active
- 2014-02-19 MX MX2015009986A patent/MX370032B/es active IP Right Grant
- 2014-02-19 DK DK14753476.2T patent/DK2958913T3/en active
- 2014-02-19 CN CN201480009397.9A patent/CN105051037B/zh active Active
- 2014-02-19 KR KR1020140019113A patent/KR101939657B1/ko active Active
- 2014-02-19 ES ES14753476T patent/ES2698359T3/es active Active
- 2014-02-19 JP JP2015559180A patent/JP6294359B2/ja active Active
- 2014-02-19 BR BR112015019794-9A patent/BR112015019794B1/pt active IP Right Grant
- 2014-02-19 WO PCT/KR2014/001336 patent/WO2014129796A1/en not_active Ceased
- 2014-02-19 SI SI201430907T patent/SI2958913T1/sl unknown
- 2014-02-19 TW TW103105447A patent/TWI582073B/zh active
- 2014-02-19 EP EP14753476.2A patent/EP2958913B1/en active Active
- 2014-02-19 RU RU2015139594A patent/RU2654483C2/ru active
- 2014-02-19 PT PT14753476T patent/PT2958913T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105051037A (zh) | 2015-11-11 |
| RU2654483C2 (ru) | 2018-05-21 |
| DK2958913T3 (en) | 2018-11-05 |
| MX370032B (es) | 2019-11-28 |
| BR112015019794A8 (pt) | 2018-08-14 |
| CN105051037B (zh) | 2018-05-18 |
| EP2958913A1 (en) | 2015-12-30 |
| PT2958913T (pt) | 2018-12-03 |
| EP2958913A4 (en) | 2016-10-05 |
| EP2958913B1 (en) | 2018-10-03 |
| TW201444794A (zh) | 2014-12-01 |
| TWI582073B (zh) | 2017-05-11 |
| KR20140104376A (ko) | 2014-08-28 |
| US20150376173A1 (en) | 2015-12-31 |
| PL2958913T3 (pl) | 2019-03-29 |
| WO2014129796A1 (en) | 2014-08-28 |
| SI2958913T1 (sl) | 2018-12-31 |
| AU2014219575B2 (en) | 2017-07-06 |
| RU2015139594A (ru) | 2017-03-27 |
| HUE039931T2 (hu) | 2019-02-28 |
| JP2016513126A (ja) | 2016-05-12 |
| US9540362B2 (en) | 2017-01-10 |
| BR112015019794B1 (pt) | 2022-09-13 |
| JP6294359B2 (ja) | 2018-03-14 |
| MX2015009986A (es) | 2015-10-05 |
| BR112015019794A2 (pt) | 2017-07-18 |
| KR101939657B1 (ko) | 2019-01-17 |
| AU2014219575A1 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2958913T3 (en) | SPHINGOSIN-1 PHOSPHATRECEPTOR AGONISTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS AN ACTIVE AGENT | |
| JP5975025B2 (ja) | イミダゾピリジン化合物 | |
| KR102122244B1 (ko) | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| BRPI0709866A2 (pt) | composto hÉtero | |
| TW201309670A (zh) | 吲哚衍生物或其藥理學上容許之鹽 | |
| WO2006030925A1 (ja) | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 | |
| KR20160135747A (ko) | B형 간염 코어 단백질 알로스테릭 조정제 | |
| JP2010529118A (ja) | オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用 | |
| JP2005530800A (ja) | ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール | |
| KR20080072688A (ko) | 옥사디아졸 유도체 | |
| JP2013514280A (ja) | スフィンゴシン１−リン酸１（ｓ１ｐ１）受容体アゴニストとして使用するためのオキサジアゾール置換インダゾール誘導体 | |
| KR20110100624A (ko) | 다발성 경화증의 치료에 유용한 옥사디아졸 융합된 헤테로사이클릭 유도체 | |
| WO2010006496A1 (zh) | 用作雌激素相关受体调节剂的化合物及其应用 | |
| CN114845996B (zh) | 一种含苯环的化合物及其应用 | |
| US20070072901A1 (en) | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | |
| CN111801333A (zh) | 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物 | |
| KR20210045390A (ko) | Fxr 수용체 작용제로서 이속사졸 | |
| CN101056855B (zh) | 含氮杂环衍生物及含有其作为活性成分的药物 |